GSK sets new environmental goals of net zero impact on climate and net positive impact on nature by 2030. For biopharma, net zero emissions across all operations and value chain by 2030 from baseline of 2020. For consumer health, reduce net scope 1+2 emissions by 100% and scope 3 emissions from source to sale by 42% by 2030, compared to 2020 baseline. 
These are 2030 targets, set against a 2016 baseline, to: reduce operational carbon emissions (Scope 1 and 2) by 20%; reduce value chain carbon emissions (Scope 3) by 25% per £ billion revenue.